{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,4]],"date-time":"2026-11-04T21:27:10Z","timestamp":1793827630705,"version":"4.6.1"},"reference-count":8,"publisher":"Ovid Technologies (Wolters Kluwer Health)","issue":"12","content-domain":{"domain":["lww.com","ovid.com"],"crossmark-restriction":true},"short-container-title":[],"published-print":{"date-parts":[[2026,12]]},"abstract":"<jats:p>\n                    This report highlights the potential role of [\n                    <jats:sup>68<\/jats:sup>\n                    Ga]Ga-FAP-2286 PET\/CT in the early detection of active tumor recurrence in a 64-year-old woman with glioblastoma multiforme (IDH-wild type, WHO grade IV), preceding definitive radiologic evidence of disease progression. Following confirmation of recurrence, the patient underwent combined chemotherapy and [\n                    <jats:sup>177<\/jats:sup>\n                    Lu]Lu-FAP-2286 radioligand therapy, resulting in a favorable partial molecular and anatomic response as demonstrated by serial PET\/CT and MRI examinations. This case illustrates the potential theranostic value of FAP-targeted imaging and radionuclide therapy in the management of recurrent glioblastoma.\n                  <\/jats:p>","DOI":"10.1097\/rlu.0000000000006693","type":"journal-article","created":{"date-parts":[[2026,10,23]],"date-time":"2026-10-23T17:02:34Z","timestamp":1792774954000},"page":"1089-1090","update-policy":"https:\/\/doi.org\/10.1097\/lww.0000000000001000","source":"Crossref","is-referenced-by-count":0,"title":["A Favorable Partial Response in Patients With Glioblastoma Multiforme Following Combined [177Lu]Lu-FAP-2286 and Chemotherapy"],"prefix":"10.1097","volume":"51","author":[{"ORCID":"https:\/\/orcid.org\/0009-0005-4759-8577","authenticated-orcid":false,"given":"Seyedeh Somayyeh","family":"Banihashemian","sequence":"first","affiliation":[{"name":"Cancer Research Center"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mohammad Esmaeil","family":"Akbari","sequence":"additional","affiliation":[{"name":"Cancer Research Center"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Elahe","family":"Pirayesh","sequence":"additional","affiliation":[{"name":"Department of Nuclear Medicine, Shohada\u2032e Tajrish Medical Center, School of Medicine, Shahid Beheshti University of Medical Sciences, Tehran, Iran."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ghasemali","family":"Divband","sequence":"additional","affiliation":[{"name":"Nuclear Medicine Center, Jam Hospital"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Abdolghafar Abolhosseini","family":"Shahrnoy","sequence":"additional","affiliation":[{"name":"Parsisotope Company, Tehran"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Reza","family":"Nami","sequence":"additional","affiliation":[{"name":"Parsisotope Company, Tehran"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Meysam","family":"Nasiri","sequence":"additional","affiliation":[{"name":"Department of Cellular and Molecular Biology, School of Biology, Damghan University, Damghan, Iran"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"276","published-online":{"date-parts":[[2026,10,20]]},"reference":[{"key":"R1-20261104","doi-asserted-by":"crossref","first-page":"19","DOI":"10.1186\/s12943-025-02533-1","article-title":"Cancer-associated fibroblasts in the tumor microenvironment: heterogeneity, crosstalk mechanisms, and therapeutic implications","volume":"25","author":"Huang","year":"2025","journal-title":"Mol Cancer"},{"key":"R2-20261104","doi-asserted-by":"crossref","first-page":"1955","DOI":"10.1172\/JCI26532","article-title":"Targeting tumor-associated fibroblasts improves cancer chemotherapy by increasing intratumoral drug uptake","volume":"116","author":"Loeffler","year":"2006","journal-title":"J Clin Invest"},{"key":"R3-20261104","doi-asserted-by":"crossref","first-page":"2621","DOI":"10.1007\/s00259-023-06211-6","article-title":"Fibroblast activation protein targeted radiotherapy induces an immunogenic tumor microenvironment and enhances the efficacy of PD-1 immune checkpoint inhibition","volume":"50","author":"Zboralski","year":"2023","journal-title":"Eur J Nucl Med Mol Imaging"},{"key":"R4-20261104","doi-asserted-by":"crossref","first-page":"4185","DOI":"10.1007\/s00259-024-06817-4","article-title":"The complete metabolic\/molecular response to chemotherapy combined with [(177)Lu]Lu-FAP-2286 in metastatic breast cancer","volume":"51","author":"Banihashemian","year":"2024","journal-title":"Eur J Nucl Med Mol Imaging"},{"key":"R5-20261104","doi-asserted-by":"crossref","first-page":"116781","DOI":"10.1016\/j.ejca.2026.116781","article-title":"[177Lu]Lu-DOTATATE PRRT and CAPTEM chemotherapy for pancreas and small bowel neuroendocrine tumours: The AGITG CONTROL NETS Multi-centre randomized trial","volume":"241","author":"Chan","year":"2026","journal-title":"Eur J Cancer"},{"key":"R6-20261104","doi-asserted-by":"crossref","first-page":"940","DOI":"10.7150\/thno.91268","article-title":"Peptide receptor radionuclide therapy combinations for neuroendocrine tumours in ongoing clinical trials: status 2023","volume":"14","author":"di Santo","year":"2024","journal-title":"Theranostics"},{"key":"R7-20261104","doi-asserted-by":"crossref","first-page":"238","DOI":"10.2967\/jnumed.124.268617","article-title":"(177)Lu-DOTATATE plus capecitabine versus (177)Lu-DOTATATE alone in patients with advanced grade 1\/2 gastroenteropancreatic neuroendocrine tumors (LuCAP): a randomized, phase 2 trial","volume":"66","author":"Satapathy","year":"2025","journal-title":"J Nucl Med"},{"key":"R8-20261104","first-page":"52","article-title":"Combined antitumor activity of [(177)Lu]Lu-FAPI-2286 and pazopanib in a sarcoma model: a preclinical theranostic study targeting fibroblast activation protein","volume":"16","author":"Tseng","year":"2026","journal-title":"EJNMMI Res"}],"container-title":["Clinical Nuclear Medicine"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.ovid.com\/10.1097\/RLU.0000000000006693","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,11,4]],"date-time":"2026-11-04T21:00:33Z","timestamp":1793826033000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.ovid.com\/10.1097\/RLU.0000000000006693"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,10,20]]},"references-count":8,"journal-issue":{"issue":"12","published-print":{"date-parts":[[2026]]}},"URL":"https:\/\/doi.org\/10.1097\/rlu.0000000000006693","relation":{},"ISSN":["0363-9762","1536-0229"],"issn-type":[{"value":"0363-9762","type":"print"},{"value":"1536-0229","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,10,20]]},"assertion":[{"value":"2026-06-17","name":"received","label":"Received","group":{"name":"publication_history","label":"Publication History"}},{"value":"2026-08-09","name":"accepted","label":"Accepted","group":{"name":"publication_history","label":"Publication History"}}]}}